Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Weekly News Recap #Phispers
1. Rmc-6236
2. Rmc6236
3. Ras Inhibitor A122
4. A1ahb
5. Schembl25774297
6. Ex-a6631b
7. Gtpl13368
8. Glxc-27997
9. Nsc852671
10. Nsc-852671
11. Hy-148439
12. Cs-0626513
13. Pyridazinacycloundecaphane-4-yl)-2-methylcyclopropane-1-carboxamide
14. (1s,2s)-n-((63s,4s,z)-11-ethyl-12-(2-((s)-1-methoxyethyl)-5-(4-methylpiperazin-1-yl)pyridin-3-yl )-10,10-dimethyl-5,7-dioxo-61,62,63,64,65,66-hexahydro-11h-8-oxa-2(4,2)-thiazola-1(5,3)-indola -6(1,3)-
| Molecular Weight | 811.0 g/mol |
|---|---|
| Molecular Formula | C44H58N8O5S |
| XLogP3 | 5.1 |
| Hydrogen Bond Donor Count | 2 |
| Hydrogen Bond Acceptor Count | 11 |
| Rotatable Bond Count | 7 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 162 |
| Heavy Atom Count | 58 |
| Formal Charge | 0 |
| Complexity | 1470 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 5 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
Daraxonrasib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Pancreatic Neoplasms.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable November 26, 2025
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)
Details : Daraxonrasib is a small molecule drug candidate, which is currently being evaluated in Phase III clinical studies for the treatment of Pancreatic Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 26, 2025
Details:
The collaboration aims to evaluate clinical-stage RAS(ON) inhibitors, including RMC-6236 (daraxonrasib), RMC-9805 (zoldonrasib) and RMC-6291 (elironrasib), in combination with ivonescimab.
Lead Product(s): Daraxonrasib,Ivonescimab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: UndisclosedProduct Type: Miscellaneous
Sponsor: Summit Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 30, 2025
Lead Product(s) : Daraxonrasib,Ivonescimab
Therapeutic Area : Oncology
Highest Development Status : Undisclosed
Partner/Sponsor/Collaborator : Summit Therapeutics
Deal Size : Undisclosed
Deal Type : Collaboration
Revolution and Summit Collaborates to Evaluate RAS(ON) Inhibitors with Ivonescimab
Details : The collaboration aims to evaluate clinical-stage RAS(ON) inhibitors, including RMC-6236 (daraxonrasib), RMC-9805 (zoldonrasib) and RMC-6291 (elironrasib), in combination with ivonescimab.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 30, 2025
Details:
The financing aims to advance the development and global commercialization of Revolution's leading RAS(ON) inhibitor portfolio, RMC-6236 (daraxonrasib), is being evaluated for RAS-mutated NSCLC.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Royalty Pharma
Deal Size: $1,250.0 million Upfront Cash: Undisclosed
Deal Type: Financing June 24, 2025
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Royalty Pharma
Deal Size : $1,250.0 million
Deal Type : Financing
Revolution Medicines Enters into $2 Billion Flexible Funding Agreement with Royalty Pharma
Details : The financing aims to advance the development and global commercialization of Revolution's leading RAS(ON) inhibitor portfolio, RMC-6236 (daraxonrasib), is being evaluated for RAS-mutated NSCLC.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
June 24, 2025
Details:
RMC-6236 (daraxonrasib) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a wide range of cancers driven by oncogenic RAS mutations.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 14, 2025
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines Doses First Patient in Phase 3 Trial of Daraxonrasib
Details : RMC-6236 (daraxonrasib) is an oral, direct RAS(ON) multi-selective inhibitor with the potential to help address a wide range of cancers driven by oncogenic RAS mutations.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 14, 2025
Details:
TNG462 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Lead Product(s): Vopimetostat,Daraxonrasib
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Revolution Medicines
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 10, 2025
Lead Product(s) : Vopimetostat,Daraxonrasib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Revolution Medicines
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TNG462 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Carcinoma, Pancreatic Ductal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 10, 2025
Details:
Daraxonrasib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2025
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Daraxonrasib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Non-Small-Cell Lung.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 18, 2025
Details:
The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $862.5 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 05, 2024
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $862.5 million
Deal Type : Public Offering
Revolution Medicines Closes $750M Offering with Full Exercise of Additional Shares
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 05, 2024
Details:
The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $750.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 03, 2024
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $750.0 million
Deal Type : Public Offering
Revolution Medicines Prices Upsized $750M Offering of Stock & Pre-Funded Warrants
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 03, 2024
Details:
The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: J.P. Morgan
Deal Size: $600.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 02, 2024
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : J.P. Morgan
Deal Size : $600.0 million
Deal Type : Public Offering
Revolution Medicines Announces Commencement of Public Offering of Common Stock
Details : The net proceeds will be used to support the clinical development of the company’s late-stage product, RMC-6236, which is being studied as a treatment for RAS-mutated Pancreatic Ductal Adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
December 02, 2024
Details:
RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for previously treated pancreatic ductal adenocarcinoma.
Lead Product(s): Daraxonrasib,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 21, 2024
Lead Product(s) : Daraxonrasib,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Revolution Medicines Doses First Patient in Phase 3 Metastatic Pancreatic Trial
Details : RMC-6236 is a small molecule, RAS(ON) multi-selective inhibitor, given orally. It is being investigated for previously treated pancreatic ductal adenocarcinoma.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 21, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
STOCK RECAP #PipelineProspector
NEWS #PharmaBuzz
18 Dec 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/12/18/3207659/0/en/Revolution-Medicines-Announces-First-Patient-Randomized-in-the-RASolute-304-Clinical-Trial-of-Daraxonrasib-in-Resectable-Pancreatic-Ductal-Adenocarcinoma-Following-Adjuvant-Chemoth.html
27 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/27/3174539/0/en/Revolution-Medicines-RAS-ON-Multi-Selective-Inhibitor-Daraxonrasib-Granted-U-S-FDA-Orphan-Drug-Designation-in-Pancreatic-Cancer.html
16 Oct 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/10/17/3168413/0/en/Revolution-Medicines-Awarded-Voucher-for-Daraxonrasib-RMC-6236-Under-FDA-Commissioner-s-National-Priority-Voucher-Pilot-Program.html
10 Sep 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/09/10/3148221/0/en/Revolution-Medicines-Shares-New-Clinical-Results-Supporting-Initiation-of-RASolute-303-a-Global-Phase-3-Registrational-Trial-of-Daraxonrasib-in-First-Line-Metastatic-Pancreatic-Duc.html
23 Jun 2025
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2025/06/23/3103444/0/en/Revolution-Medicines-Announces-FDA-Breakthrough-Therapy-Designation-for-Daraxonrasib-in-Previously-Treated-Metastatic-Pancreatic-Cancer-with-KRAS-G12-Mutations.html
ABOUT THIS PAGE
65
PharmaCompass offers a list of Daraxonrasib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Daraxonrasib manufacturer or Daraxonrasib supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Daraxonrasib manufacturer or Daraxonrasib supplier.
PharmaCompass also assists you with knowing the Daraxonrasib API Price utilized in the formulation of products. Daraxonrasib API Price is not always fixed or binding as the Daraxonrasib Price is obtained through a variety of data sources. The Daraxonrasib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Daraxonrasib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Daraxonrasib, including repackagers and relabelers. The FDA regulates Daraxonrasib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Daraxonrasib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Daraxonrasib supplier is an individual or a company that provides Daraxonrasib active pharmaceutical ingredient (API) or Daraxonrasib finished formulations upon request. The Daraxonrasib suppliers may include Daraxonrasib API manufacturers, exporters, distributors and traders.
Daraxonrasib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Daraxonrasib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Daraxonrasib GMP manufacturer or Daraxonrasib GMP API supplier for your needs.
A Daraxonrasib CoA (Certificate of Analysis) is a formal document that attests to Daraxonrasib's compliance with Daraxonrasib specifications and serves as a tool for batch-level quality control.
Daraxonrasib CoA mostly includes findings from lab analyses of a specific batch. For each Daraxonrasib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Daraxonrasib may be tested according to a variety of international standards, such as European Pharmacopoeia (Daraxonrasib EP), Daraxonrasib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Daraxonrasib USP).
Share 
